hydrazine has been researched along with Hepatitis B, Chronic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Feng, Q; Hu, X; Li, N; Liu, A; Ma, S; Peng, J; Sheng, Z; Zhang, Y | 1 |
| Fujiyama, S; Hattori, T; Katsura, K; Kawaguchi, T; Komori, A; Nakamuta, M; Oketani, M; Sakisaka, S; Sasaki, Y; Sata, M; Seike, M; Tanaka, M; Watanabe, H | 1 |
1 trial(s) available for hydrazine and Hepatitis B, Chronic
| Article | Year |
|---|---|
Efficacy and safety of eltrombopag in Japanese patients with chronic liver disease and thrombocytopenia: a randomized, open-label, phase II study.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Chronic Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematologic Agents; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Hydrazines; Liver Diseases; Male; Middle Aged; Platelet Count; Pyrazoles; Thrombocytopenia; Treatment Outcome | 2012 |
1 other study(ies) available for hydrazine and Hepatitis B, Chronic
| Article | Year |
|---|---|
Eltrombopag inhibits Type I interferon-mediated antiviral signaling by decreasing cellular iron.
Topics: Adult; Animals; Antiviral Agents; Benzoates; Cell Survival; Cells, Cultured; Female; Hepatitis B, Chronic; Humans; Hydrazines; Interferon-alpha; Iron; Leukocytes, Mononuclear; Male; Mice; Mice, Inbred C57BL; Middle Aged; Pyrazoles; Receptors, Thrombopoietin; THP-1 Cells; Thrombocytopenia | 2021 |